Literature DB >> 8244464

Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human gamma 1.

P Lane1, W Gerhard, S Hubele, A Lanzavecchia, F McConnell.   

Abstract

We report the construction and expression of a fusion protein made from the extracellular portion of the mouse CTLA-4 gene and the constant region of human IgG1. This fusion protein behaves like an antibody to mouse B7/BB1, binding to activated B cells and purified dendritic cells. In addition, we found it to bind to activated T cells. The fusion protein interfered with the ability of antigen-pulsed antigen-presenting cells to induce proliferation of T-cell clones, although the degree of inhibition varied. These findings are discussed in the light of the physiological activation of T cells in secondary lymphoid organs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244464      PMCID: PMC1422105     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation.

Authors:  R M Torres; E A Clark
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

Review 2.  Myeloma based expression system for production of large mammalian proteins.

Authors:  A Traunecker; F Oliveri; K Karjalainen
Journal:  Trends Biotechnol       Date:  1991-04       Impact factor: 19.536

Review 3.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.

Authors:  D L Mueller; M K Jenkins; R H Schwartz
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34 (H1N1) which are recognized by class II-restricted T cells from BALB/c mice.

Authors:  W Gerhard; A M Haberman; P A Scherle; A H Taylor; G Palladino; A J Caton
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro.

Authors:  D M Sansom; N D Hall
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

Review 6.  Role of the CD28 receptor in T-cell activation.

Authors:  C H June; J A Ledbetter; P S Linsley; C B Thompson
Journal:  Immunol Today       Date:  1990-06

7.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

Authors:  C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

8.  A new member of the immunoglobulin superfamily--CTLA-4.

Authors:  J F Brunet; F Denizot; M F Luciani; M Roux-Dosseto; M Suzan; M G Mattei; P Golstein
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

9.  CTLA-4 is a second receptor for the B cell activation antigen B7.

Authors:  P S Linsley; W Brady; M Urnes; L S Grosmaire; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

10.  Presentation of antigen by mixed isotype class II molecules in normal H-2d mice.

Authors:  G Ruberti; K S Sellins; C M Hill; R N Germain; C G Fathman; A Livingstone
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  25 in total

1.  Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.

Authors:  E Z Wolpert; M Petersson; B J Chambers; J K Sandberg; R Kiessling; H G Ljunggren; K Kärre
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice.

Authors:  M Smith; J M Burchell; R Graham; E P Cohen; J Taylor-Papadimitriou
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

3.  Anergic self-reactive B cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions.

Authors:  J M Eris; A Basten; R Brink; K Doherty; M R Kehry; P D Hodgkin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  Antiviral immune responses in CTLA4 transgenic mice.

Authors:  C Zimmermann; P Seiler; P Lane; R M Zinkernagel
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Hemopoiesis in long-term stroma-dependent cultures from lymphoid tissue: production of cells with myeloid/dendritic characteristics.

Authors:  K Ni; H C O'Neill
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-04       Impact factor: 2.416

Review 6.  The role of dendritic cells in cutaneous immunity.

Authors:  M B Lappin; I Kimber; M Norval
Journal:  Arch Dermatol Res       Date:  1996-03       Impact factor: 3.017

7.  Inhibition of corneal allograft reaction by CTLA4-Ig.

Authors:  F Hoffmann; E P Zhang; T Pohl; U Kunzendorf; J Wachtlin; S Bulfone-Paus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

8.  The bullseye synapse formed between CD4+ T-cell and staphylococcal enterotoxin B-pulsed dendritic cell is a suppressive synapse in T-cell response.

Authors:  Wei Lin; Zhichao Fan; Yuanzhen Suo; Yuting Deng; Min Zhang; Jiyang Wang; Xunbin Wei; Yiwei Chu
Journal:  Immunol Cell Biol       Date:  2014-10-07       Impact factor: 5.126

9.  Resting and activated T cells display different requirements for CD8 molecules.

Authors:  Z Cai; J Sprent
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

10.  PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.

Authors:  Debora Franceschini; Marino Paroli; Vittorio Francavilla; Melissa Videtta; Stefania Morrone; Giancarlo Labbadia; Antonella Cerino; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.